Trametinib
- Generic Name
- Trametinib
- Brand Names
- Mekinist, Spexotras
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23FIN5O4
- CAS Number
- 871700-17-3
- Unique Ingredient Identifier
- 33E86K87QN
- Background
Trametinib is an orally bioavailable mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 inhibitor. It was first approved by the FDA in May 2013 for the treatment of melanoma. It was later approved by Health Canada on July 18, 2013 and by the European Commission on June 30, 2014. Trametinib is currently approved to treat a variety of c...
- Indication
Trametinib is indicated as monotherapy for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.
It is used in combination with dabrafenib for the:
...
- Associated Conditions
- Advanced Non-Small Cell Lung Cancer (NSCLC), Locally Advanced Anaplastic Thyroid Cancer, Low-Grade Glioma, Melanoma, Metastatic Anaplastic Thyroid Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Stage III Melanoma, Unresectable Melanoma, Unresectable or Metastatic Solid Tumors
- Associated Therapies
- -
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 12
- Registration Number
- NCT06653517
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Cook Children's Health Care System
- Target Recruit Count
- 75
- Registration Number
- NCT06582745
- Locations
- 🇺🇸
Cook Children's Health Care System, Fort Worth, Texas, United States
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 80
- Registration Number
- NCT06532149
- Locations
- 🇮🇹
Fondazione Policlinico Gemelli IRCCS, Rome, Italy
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 264
- Registration Number
- NCT06475989
- Locations
- 🇺🇸
Idaho Urologic Institute-Meridian, Meridian, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
🇺🇸Kootenai Clinic Cancer Services - Sandpoint, Sandpoint, Idaho, United States
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06456138
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 470
- Registration Number
- NCT06346067
- Locations
- 🇺🇸
Texas Oncology- Austin Midtown, Austin, Texas, United States
🇺🇸Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Erasca, Inc.
- Target Recruit Count
- 115
- Registration Number
- NCT05907304
- Locations
- 🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Se Jun Park
- Target Recruit Count
- 30
- Registration Number
- NCT05876806
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 58
- Registration Number
- NCT05849662
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT05677373
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.